Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Monoclonal antibodies (mAbs) are multidomain glycosylated proteins that mediate antigen binding, among other protein-protein interactions, which makes them successful therapeutics. However, in many cases, adverse physicochemical properties can affect their antigen-binding abilities, compromising therapeutic potential. Hence, structural characterization of these biotherapeutics is strongly desired to predict and possibly redesign better variants. The presence of glycosylation deters the use of isotope labeling, which is required for the structure determination of these intact proteins (MW ∼150 kDa) by Nuclear Magnetic Resonance Spectroscopy (NMR). In this work, NMR-based structural fingerprinting of three therapeutic mAbs at natural abundance was performed. The robustness of the mAb fingerprints was demonstrated by comparing them with two Fc-fusion proteins. A peptide-based assignment methodology was adopted for these intact proteins, which identified the presence of the flexible hinge segment in mAbs in solution. The plasticity of the hinge was demonstrated by the changes in fingerprints in the presence of the cognate antigen and nonantigen. The methodology underlines the importance of the hinge in antigen recognition beyond the canonical role of Complementarity-Determining Regions (CDRs). This methodology lays the dynamic basis of antibody function in solution.

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.biochem.5c00274DOI Listing

Publication Analysis

Top Keywords

monoclonal antibodies
8
antigen recognition
8
intact proteins
8
profiling hinge
4
hinge plasticity
4
plasticity intact
4
intact monoclonal
4
antigen
4
antibodies antigen
4
recognition monoclonal
4

Similar Publications

Objective: To evaluate the clinical efficacy of tocilizumab, a interleukin-6 (IL-6) receptor blocker, for the treatment of acute necrotizing encephalopathy (ANE).

Methods: PubMed, Cochrane Library, Embase, and Web of Science were searched for systematic review based on PRISMA guidelines. ANE patients treated with and without tocilizumab were included.

View Article and Find Full Text PDF

Egg yolk immunoglobulin (IgY) has emerged as a promising alternative to monoclonal antibodies (mAbs) due to its facile extraction, higher yield, and greater tolerance to organic solvents. This work developed a selective IgY antibody against bongkrekic acid (BA) and isobongkrekic acid (IsoBA), the lethal toxins produced by Burkholderia gladioli pv. Cocovenenans (BGC), which led to severe food poisoning incidents and resulted in casualties.

View Article and Find Full Text PDF

Evaluation of two IgG-scFv bispecific antibodies for neutralizing Omicron variants of SARS-CoV-2.

J Virol Methods

September 2025

Laboratorio de Inmunología, Centro de Investigación en Alimentación y Desarrollo, A.C. Hermosillo, Sonora, Mexico. Electronic address:

Bispecific antibodies (bsAbs) offer an alternative to monoclonal antibody (mAb) cocktails for addressing the loss of efficacy due to the rapid emergence of SARS-CoV-2 mutants. The structure and specificity of the parental antibodies influence the development of a highly neutralizing bsAb. To design an effective bsAb, the recognition of 44 single-chain fragment variable (scFv) antibodies against variants of SARS-CoV-2 was evaluated, along with an assessment of their ability to competitively bind to the receptor-binding domain (RBD) compared to the most potent neutralizing mAbs.

View Article and Find Full Text PDF

Observational analysis of biological remission as a treatment target for severe asthma: UK severe asthma registry.

J Allergy Clin Immunol Pract

September 2025

Wellcome Wolfson Institute for Experimental Medicine, Queen's University Belfast, UK; Belfast Health and Social Care Trust, Belfast, UK.

Background: The aim of biologic therapies in severe asthma is inhibition of T2 inflammatory pathways.

Objective: We hypothesized that patients who achieve complete suppression of IL-5 & IL4/IL13 pathways with biologic therapy (FeNO <20ppb & blood eosinophil count (BEC) <0.15x10ˆ9, 'biological remission') would have better outcomes than patients with incomplete suppression of T2 biology.

View Article and Find Full Text PDF

The development of continuous-release devices or injectables for the long-term delivery of biologics is of great interest, especially monoclonal antibodies (mAbs) that require frequent, high-dose injections. Preclinical testing of these technologies in murine models is necessary for clinical translation; however, xenogeneic responses to the mAb and foreign body responses to the implants or injectables can confound results. Immune system knockout (KO) models that affect immune cells are often used in these experiments, but the effects of KO models on mAb pharmacokinetics (PK) are not well characterized.

View Article and Find Full Text PDF